DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article Summary
HOLD- Dyne Therapeutics Inc. (Nasdaq: DYN) announced that it has granted inducement equity awards to 6 newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4) The clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases received non-statutory stock options to purchase up to 126,000 shares of common stock at a per share exercise price equal to closing price of Dyne's common stock on June 16, 2026, and restricted stock units with respect to an aggregate of 40,100 shares of the common stock.
- The stock options have a ten-year term and are scheduled to vest over four years with 25% of original number of shares vesting on first anniversary of applicable employee's start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee's continued service to Dyne through applicable vesting dates.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 14.6% | 25% | 35.0 ptsBelow Screener (14.6%) - Modest outlook |
| Target Price Upside ? | 93.2% | 20% | 100.0 ptsMassive Upside (93.2%) - Target: $38.25 vs Current: $19.80 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -20.8% | 15% | 40.0 ptsMild Pullback (-20.8%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.